GUARDANT HEALTH INC (GH) Stock Overview
NASDAQ:GH - US40131M1099 - Common Stock
GH Key Statistics, Chart & Performance
The current stock price of GH is 63.545 USD. In the past month the price increased by 46.42%. In the past year, price increased by 147.97%.
GH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.35 | 91.25B | ||
| CI | THE CIGNA GROUP | 10.67 | 80.02B | ||
| LH | LABCORP HOLDINGS INC | 18.42 | 23.18B | ||
| DGX | QUEST DIAGNOSTICS INC | 19 | 20.10B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 12.38 | 14.75B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 112.32 | 14.72B | ||
| HIMS | HIMS & HERS HEALTH INC | 55.21 | 9.98B | ||
| DVA | DAVITA INC | 14.22 | 9.85B | ||
| CHE | CHEMED CORP | 20.39 | 6.65B | ||
| RDNT | RADNET INC | 198.33 | 5.49B | ||
| OPCH | OPTION CARE HEALTH INC | 21.18 | 4.64B | ||
| CRVL | CORVEL CORP | 49.4 | 4.61B |
Related stock screener links
About GH
Company Profile
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Company Info
GUARDANT HEALTH INC
3100 Hanover Street
Palo Alto CALIFORNIA 94063 US
CEO: Helmy Eltoukhy
Employees: 2010
Phone: 18556988887
GUARDANT HEALTH INC / GH FAQ
What is the stock price of GUARDANT HEALTH INC today?
The current stock price of GH is 63.545 USD. The price increased by 0.18% in the last trading session.
What is the ticker symbol for GUARDANT HEALTH INC stock?
The exchange symbol of GUARDANT HEALTH INC is GH and it is listed on the Nasdaq exchange.
On which exchange is GH stock listed?
GH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GUARDANT HEALTH INC stock?
34 analysts have analysed GH and the average price target is 60.64 USD. This implies a price decrease of -4.57% is expected in the next year compared to the current price of 63.545. Check the GUARDANT HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GUARDANT HEALTH INC worth?
GUARDANT HEALTH INC (GH) has a market capitalization of 7.92B USD. This makes GH a Mid Cap stock.
How many employees does GUARDANT HEALTH INC have?
GUARDANT HEALTH INC (GH) currently has 2010 employees.
What are the support and resistance levels for GUARDANT HEALTH INC (GH) stock?
GUARDANT HEALTH INC (GH) has a support level at 58.49 and a resistance level at 63.44. Check the full technical report for a detailed analysis of GH support and resistance levels.
Is GUARDANT HEALTH INC (GH) expected to grow?
The Revenue of GUARDANT HEALTH INC (GH) is expected to grow by 26.02% in the next year. Check the estimates tab for more information on the GH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GUARDANT HEALTH INC (GH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GH, evaluating the profitability, health, valuation and growth aspects
- GUARDANT HEALTH INC (GH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GUARDANT HEALTH INC (GH) Sales and EPS estimates to see what analysts future expectations are.
- GUARDANT HEALTH INC (GH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GUARDANT HEALTH INC (GH) Insider and Institutional Ownership to learn about the owners and their transactions.
- GUARDANT HEALTH INC (GH) Stock Chart to make your own analysis
- GUARDANT HEALTH INC (GH) Latest news and press-releases to stay up to date.
Does GUARDANT HEALTH INC (GH) stock pay dividends?
GH does not pay a dividend.
When does GUARDANT HEALTH INC (GH) report earnings?
GUARDANT HEALTH INC (GH) will report earnings on 2025-11-04, after the market close.
What is the Price/Earnings (PE) ratio of GUARDANT HEALTH INC (GH)?
GUARDANT HEALTH INC (GH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.4).
What is the Short Interest ratio of GUARDANT HEALTH INC (GH) stock?
The outstanding short interest for GUARDANT HEALTH INC (GH) is 7.89% of its float. Check the ownership tab for more information on the GH short interest.
GH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GH. When comparing the yearly performance of all stocks, GH is one of the better performing stocks in the market, outperforming 96.73% of all stocks.
GH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GH. GH may be in some trouble as it scores bad on both profitability and health.
GH Financial Highlights
Over the last trailing twelve months GH reported a non-GAAP Earnings per Share(EPS) of -3.4. The EPS decreased by -1.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.07% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GH Forecast & Estimates
34 analysts have analysed GH and the average price target is 60.64 USD. This implies a price decrease of -4.57% is expected in the next year compared to the current price of 63.545.
For the next year, analysts expect an EPS growth of 10.91% and a revenue growth 26.02% for GH